CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Maxygen, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Maxygen, Inc.
Suite 616, 411 Borel Avenue
Phone: (650) 241-2292p:650 241-2292 SAN MATEO, CA  94402  United States Fax: (650) 257-5892f:650 257-5892

This company ceased filing statements with the SEC on 11/1/2013.
On 8/12/2013, the stockholders of the Company voted to approve the liquidation and dissolution of the Company pursuant to a Plan of Complete Liquidation and Dissolution, which was approved by the Board of Directors. The Company intends to file a certificate of dissolution with the Delaware Secretary of State on 8/29/2013 in accordance with the Plan of Dissolution. The Company also notified The NASDAQ Stock Market that it intends to file its certificate of dissolution and requested that NASDAQ suspend the trading of the Common Stock, effective as of the close of trading on 8/29/2013. The Company also requested that NASDAQ delist the Common Stock from The NASDAQ Global Market as soon as practicable thereafter.
This company is no longer actively traded on any major stock exchange.

Business Summary
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company’s interests in Perseid Therapeutics LLC, the Company’s former subsidiary, which included all of the Company’s research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company’s wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201312/31/2012YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Chief Executive Officer, Chief Financial Officer IsaacStein 66 7/1/2013 5/1/1996
General Counsel, Secretary John M.Borkholder 44 3/16/2011 3/4/2008
Independent Director Louis G.Lange 65 12/9/2005 12/9/2005
3 additional Officers and Directors records available in full report.

Business Names
Business Name
Maxygen ApS
Maxygen Holdings (U.S.), Inc.

General Information
Number of Employees: 6 (As of 12/31/2012)
Outstanding Shares: 27,788,749 (As of 7/31/2013)
Shareholders: 160
Stock Exchange: NASD
Federal Tax Id: 770449487
Fax Number: (650) 257-5892


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023